PNC Financial Services Group
CADL icon

PNC Financial Services Group’s Candel Therapeutics CADL Stock Holding History

PNC Financial Services Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$927 Sell
90
-64
-42% -$483 ﹤0.01% 4859
2026
Q1 		$754 Buy
154
+149
+2,980% +$811 ﹤0.01% 4817
2025
Q4 		$28 Sell
5
-59
-92% -$317 ﹤0.01% 5121
2025
Q3 		$326 Buy
+64
New +$370 ﹤0.01% 4877

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PNC Financial Services Group's CADL Position: Q2 2026 in Review

PNC Financial Services Group reduced its Candel Therapeutics (CADL) stake by 42% in Q2 2026, selling an estimated $483 and leaving 90 shares worth $927. The position accounts for ﹤0.01% of the portfolio, ranked #4859.

PNC Financial Services Group first reported a position in CADL in Q3 2025 and has held it in 4 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • PNC Financial Services Group held 90 shares of Candel Therapeutics worth $927 as of Q2 2026.
  • PNC Financial Services Group sold 64 Candel Therapeutics shares in Q2 2026, an estimated $483.
  • Candel Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4859 holding.
  • PNC Financial Services Group first reported a position in Candel Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.